<DOC>
	<DOCNO>NCT01202786</DOCNO>
	<brief_summary>The aim study cancer unknown primary ( CUP ) patient , compare cost-effectiveness miRview™ mets test conventional work-up identifying primary tumor site .</brief_summary>
	<brief_title>Cost-effectiveness Study miRview™ Mets Patients With Cancer Unknown Primary ( CUP )</brief_title>
	<detailed_description>Thousands patient diagnose year metastatic cancer ; however , 3-5 % diagnosed Cancer Unknown Primary ( CUP ) . In order identify optimal treatment plan individual patient CUP , primary tumor site must identify . Patients undergo wide range costly , time-consuming , inefficient test identify primary site origin , often avail . In era target therapy , accurate diagnosis primary tumor crucial . miRview™ mets new molecular diagnostic tool identifies tissue-of-origin metastatic tumor , 90 % sensitivity .</detailed_description>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<criteria>1 . Patients present histologicallyconfirmed metastatic cancer initial workup consist detailed medical history , physical examination , basic laboratory study , histopathological review biopsy material , CT scan chest abdomen pelvis fail identify primary site . 2 . Older 18 year 3 . Performance status &lt; 2 4. life expectancy &gt; 3 month 5 . ANC &gt; 1500 6 . Platelets &gt; 100,000 bone marrow involve 7 . Hb &gt; 9 8 . Creatinine &lt; 2 9 . LFTS &lt; x5 normal 10 . Histology proven malignancy 11 . Enough material miRview test ( 10 slice 10 micrometer section ) 12 . Member Clalit HMO 1 . Patients unable unwilling sign inform consent form 2 . Under 18 year old 3 . Performance status &gt; 2 4. life expectancy &lt; 3 month 5 . ANC &lt; 1500 6 . Platelets &lt; 100,000 marrow involve 7 . Hb &lt; 9 8 . Creatinine &gt; 2 9 . LFTS &gt; x5 normal 10 . Not member Clalit HMO</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer Unknown Primary Site ( CUP )</keyword>
</DOC>